Juan Liu

发表

Analysis and classification of DNA-binding sites in single-stranded and double-stranded DNA-binding proteins using protein information.

Wei Wang, Y. Xiong, Wei Wang, 2014, IET systems biology.

A novel sensor for the detection of alkaline phosphatase activity based on the self-assembly of Eu3+-doped oxide nanoparticles and heptamethine cyanine dye

Min Liu, Yi Cui, Juan Liu, 2016 .

C-myc/miR-150/EPG5 axis mediated dysfunction of autophagy promotes development of non-small cell lung cancer

Mao Ye, Xiaojuan Xiao, Jing Liu, 2019, Theranostics.

Synthesis and in vitro biological evaluation of novel quinazoline derivatives.

Li Chen, Juan Liu, Yaling Zhang, 2017, Bioorganic & medicinal chemistry letters.

Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.

Li Chen, Juan Liu, Yaling Zhang, 2017, European journal of medicinal chemistry.

Discovery of 2-((3-Acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor.

Qingsong Liu, Xiaofei Liang, Zhenquan Hu, 2017, Journal of medicinal chemistry.

Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas.

Qingsong Liu, Xiaofei Liang, Q. Liu, 2021, Journal of medicinal chemistry.

Discovery of a highly potent and selective Bruton’s tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma

Qingsong Liu, Q. Liu, Juan Liu, 2020, Signal Transduction and Targeted Therapy.

Repurposing of the FGFR inhibitor AZD4547 as a potent inhibitor of necroptosis by selectively targeting RIPK1

Q. Liu, Juan Liu, Ao-li Wang, 2022, Acta Pharmacologica Sinica.

Discovery of Pyrrolo[2,3-d]pyrimidine derivatives as potent and selective colony stimulating factor 1 receptor kinase inhibitors.

Q. Liu, Xiaofei Liang, Juan Liu, 2022, European journal of medicinal chemistry.

Quinazoline-1-deoxynojirimycin hybrids as high active dual inhibitors of EGFR and α-glucosidase.

Li Chen, Juan Liu, Yaling Zhang, 2017, Bioorganic & medicinal chemistry letters.

Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences

C. Liang, Liangdan Sun, Qingsong Liu, 2020, Molecular Biomedicine.

BMP4 is Involved in the Chemoresistance of Myeloid Leukemia Cells Through Regulating Autophagy–Apoptosis Balance

Fang-ping Chen, Juan Liu, Xielan Zhao, 2013, Cancer investigation.

Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)

Qingsong Liu, C. Yun, Zhenquan Hu, 2016, Oncotarget.

Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.

Qingsong Liu, Zheng Zhao, Hong Wu, 2015, Journal of medicinal chemistry.

Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML.

Zhenquan Hu, Q. Liu, Hong Wu, 2017, Journal of medicinal chemistry.

Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors

Qingsong Liu, X. Liu, X. Xiao, 2019, Therapeutic advances in medical oncology.

Identification of Small-Molecule Inhibitors for Osteosarcoma Targeted Therapy: Synchronizing In Silico, In Vitro, and In Vivo Analyses

M. Ramalingam, Zhihong Dong, Juan Liu, 2022, Frontiers in Bioengineering and Biotechnology.

Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode

Qingsong Liu, C. Yun, Hong Wu, 2017, Oncotarget.

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells

N. Gray, Qingsong Liu, Jinhua Wang, 2015, Oncotarget.

All-Trans Retinoic Acid Exerts Selective Anti-FLT3-ITD Acute myeloid leukemia Efficacy through Downregulating Chk1 Kinase.

Qingsong Liu, Zong-ru Jiang, Juan Liu, 2020, Cancer letters.

Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models

Q. Liu, Hong Wu, Zong-ru Jiang, 2019, Investigational New Drugs.

Adsorption of arsenic(V) on bone char: batch, column and modeling studies

Wei Zhang, F. Dong, Weiqing Wang, 2014, Environmental Earth Sciences.

The Passive Treatment of Arsenic-containing Acid Mine Drainage and Using Manganese-coated Bone Char and Evaluation on its Neutralization Ability

S. Deng, Juan Liu, Jing Liu, 2014 .

Nintedanib overcomes drug resistance from upregulation of FGFR signalling and imatinib‐induced KIT mutations in gastrointestinal stromal tumours

Qingsong Liu, Hong Wu, Zong-ru Jiang, 2022, Molecular oncology.

Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I "Gatekeeper" Mutant of cKIT Kinase.

Qingsong Liu, Zhenquan Hu, Hong Wu, 2016, Journal of medicinal chemistry.

Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment.

Q. Liu, Zong-ru Jiang, Juan Liu, 2023, European journal of pharmacology.

Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding.

Qingsong Liu, Zhenquan Hu, Juan Liu, 2017, Journal of medicinal chemistry.

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML

J. Griffin, E. Weisberg, Zheng Zhao, 2016, Oncotarget.

Experimental and model studies on comparison of As(III and V) removal from synthetic acid mine drainage by bone char

Wei Zhang, F. Dong, Weiqing Wang, 2014, Mineralogical Magazine.

Distinguishing single-stranded and double-stranded DNA binding proteins based on structural information

Wei Wang, Juan Liu, Wei Wang, 2013, 2013 IEEE International Conference on Bioinformatics and Biomedicine.

Surface shapes and surrounding environment analysis of single‐ and double‐stranded DNA‐binding proteins in protein‐DNA interface

Lin Sun, Wei Wang, Lin Sun, 2016, Proteins.

Discovery of Pyrazolo[1,5-a]pyrimidine derivative as a potent and selective PI3Kγ/δ dual inhibitor.

Q. Liu, Juan Liu, F. Zou, 2023, European journal of medicinal chemistry.

Qingsong Liu, Zhenquan Hu, Hong Wu, 2016, Journal of medicinal chemistry.

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells

N. Gray, Qingsong Liu, Jinhua Wang, 2015, Oncotarget.

Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.

Li Chen, Juan Liu, Yaling Zhang, 2017, European journal of medicinal chemistry.